Cargando…

Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report

Esophageal neuroendocrine carcinoma (ENEC) is an extremely rare tumor with highly malignant potential, rapid growth, and a poor prognosis. Advanced extrapulmonary neuroendocrine carcinoma should be treated with chemotherapeutic regimens suitable for small cell lung cancer. However, ENEC has no clear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yanqi, Liu, Xiaoyu, Liang, Honglu, Liu, Weihua, Wang, Haiyan, Li, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387792/ https://www.ncbi.nlm.nih.gov/pubmed/37498227 http://dx.doi.org/10.1177/03000605231187942

Ejemplares similares

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
por: Cai, Ruoxue, et al.
Publicado: (2023)

Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib—a case report
por: Li, Yu-Feng, et al.
Publicado: (2022)

Treatment of Metastatic Primary Extramammary Paget Disease With Combination Anlotinib and Tislelizumab: A Case Report and Review of the Literature
por: Yin, Xin, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
por: Li, Teng, et al.
Publicado: (2023)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
por: Dai, Shuang, et al.
Publicado: (2022)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
por: Ye, Dingwei, et al.
Publicado: (2020)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib
por: Lin, Cheng, et al.
Publicado: (2023)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report
por: Liu, Liang, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
por: Shi, Fenghao, et al.
Publicado: (2022)

Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report
por: Qu, Fanjie, et al.
Publicado: (2021)

Tislelizumab for squamous lung cancer combined with basal cell carcinoma of the skin: A case report
por: Wu, Ming-Jun, et al.
Publicado: (2023)

Tislelizumab-related enteritis successfully treated with adalimumab: A case report
por: Chen, Na, et al.
Publicado: (2022)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
por: Ji, Xiang, et al.
Publicado: (2022)

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
por: Zhou, Chongchong, et al.
Publicado: (2023)

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy
por: Honma, Yoshitaka, et al.
Publicado: (2019)

Safety and efficacy of tislelizumab plus chemotherapy for first‐line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma
por: Qiu, Hai‐Bo
Publicado: (2020)

Zanubrutinib, Alone and in Combination With Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia
por: Tam, Constantine, et al.
Publicado: (2023)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Tislelizumab Induced Vitiligo-Like Depigmentation in a Chinese Patient with Oesophageal Squamous Cell Carcinoma
por: Li, Ping, et al.
Publicado: (2022)

Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study
por: Wu, Wen-Jie, et al.
Publicado: (2023)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy
por: Cai, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ku93jqof370ht3cn5kc1hltu0i